tbuckley/cabot-search huggingface dataset:
AB0183 Methotrexate induced apoptosis in synoviocyte of rheumatoid arthritis
Authors: S.Y. Lee, S.W. Lee, W.T. Chung, C.W. Lee, E.J. Kang, J.-H. Bae
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Methotrexate (MTX) was the corner stone treatment of rheumatoid arhtirits. So for long time, MTX was used in rheumatoid arhtirits treatment with other Immunosuppressive drug. There were many hypothesis in mechanism of MTX on RA treatments, but accurate mechanism of MTX was not known <h3>Objectives</h3> To investigate the apoptotic mechanism of MTX in synoviocyte of rhuematoid arhtirits <h3>Methods</h3> Synovial cells were cultured from synovial fluid of Rhuematoid arhtirits (RA) patients and Osteoarhtirtis (OA) patients. In each group, the subculture was conducted for 5-6 passages and synovioctes was treated with 300μM 500μM MTX directly. In 400μM The cell viability was observed and apoptosis of synoviocyte was measured by flow cytometry <h3>Results</h3> MTX treated synovial cell death was higher RA than OA in 300μM 500μM MTX, In 400μM MTX, high Sub-G1 pick was observed and continued to 24 hours in RA synoviocytes <h3>Conclusions</h3> Apoptosis was the one of MTX mechasnism in RA treatment and RA synoviocytes apoptosis may be one of tool for RA treatment in the future <h3>References</h3> Determinants of Red Blood Cell Methotrexate Polyglutamate Concentrations in Rheumatoid Arthritis Patients Receiving Long-Term Methotrexate Treatment Lisa K. Stamp, John L. O'Donnell, Peter T. Chapman, Mei Zhang, Christopher Frampton, Jill James, Murray L. Barclay. Arthritis &amp; Rheumatism Vol. 60, No. 8, August 2009, pp 2248–2256. <h3>Disclosure of Interest</h3> None Declared
Abstract 3670: The role of reactive oxygen species in anticancer effects of diallyl trisulfide, a bioactive component of garlic.
Authors: Julie A. Arlotti, Kumar Chandra-Kuntal, Shivendra V. Singh
Journal: Cancer Research (2013)

Abstract Diallyl trisulfide (DATS) is a bioactive component of processed garlic with in vivo activity against chemically-induced as well as oncogene-driven cancer in rodent models. However, the mechanisms underlying anticancer effects of DATS (eg, growth inhibition, apoptosis induction, and suppression of migration in cancer cells) are not fully understood. The present study reveals a critical role for reactive oxygen species (ROS) in cellular anticancer responses to DATS. Exposure of human breast cancer cells (MDA-MB-231 and MCF-7) as well as a cell line derived from spontaneously developing mammary tumor of a MMTV-neu transgenic mouse (BRI-JM04) to DATS resulted in dose-dependent inhibition of cell viability and apoptosis induction. Interestingly, a non-tumorigenic normal human mammary cell line (MCF-10A) was resistant to growth inhibition and apoptosis induction by DATS. The DATS-induced apoptosis in MDA-MB-231, MCF-7, and BRI-JM04 cells was associated with ROS production as evidenced by fluorescence microscopy and flow cytometry using a chemical probe (MitoSOX Red). Ectopic expression of Cu,Zn-superoxide dismutase (Cu,Zn-SOD) as well as Mn-SOD conferred significant protection against DATS-induced ROS production and apoptotic cell death. The DATS treatment caused activation of Bax and Bak, and activation of Bak was nearly fully abolished by overexpression of Mn-SOD. Likewise, inhibition of MDA-MB-231 and MCF-7 cell migration resulting from DATS treatment was partially but statistically significantly attenuated by stable overexpression of Cu,Zn-SOD and Mn-SOD. This protection against inhibition of cell migration was attributable to abrogation of DATS-mediated induction of E-cadherin and suppression of vimentin. These results indicate that ROS play an important role in anticancer effects of DATS at least in human breast cancer cells. This study was supported by grant CA113363-07 awarded by the National Cancer Institute. Citation Format: Julie A. Arlotti, Kumar Chandra-Kuntal, Shivendra V. Singh. The role of reactive oxygen species in anticancer effects of diallyl trisulfide, a bioactive component of garlic. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3670. doi:10.1158/1538-7445.AM2013-3670
542 THE ENTEBE STUDY: SAFETY AND EFFICACY OF ENTECAVIR PLUS TENOFOVIR IN ADULTS WITH CHRONIC HEPATITIS B AND PREVIOUS NUCLEOS(T)IDE TREATMENT FAILURE
Authors: K. Simon, M. Diculescu, H.L.A. Janssen, F. Zoulim, J. Petersen, P. Marcellin, I. Klauck, M. Pans, S. Bendahmane, M. Jablkowski
Journal: Journal of Hepatology (2012)
FDG PET/CT Findings of Ménétrier Disease
Authors: Aisheng Dong, Ling Zhang, Tianlin He, Changjing Zuo
Journal: Clinical Nuclear Medicine (2016)

Ménétrier disease is a very rare chronic gastric disorder characterized by gastric mucosal hypertrophy. We present a case of Ménétrier disease with CT, MRI, and FDG PET/CT findings. Enhanced CT and MRI showed diffuse thickened mucosa of the greater curvature and elongated mucosa of the antrum with remarkable enhancement. The early and delayed FDG PET/CT showed increased FDG uptake of these thickened mucosa. The increased FDG uptake may be due to the mucosal inflammation. This case indicates Ménétrier disease should be included in the differential diagnosis of abnormal gastric FDG accumulation along with tumor and nontumor processes.
Scientists Set Priorities for Lung Cancer Intervention
Authors: L. Schwab
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Scientists Set Priorities for Lung Cancer Intervention Get access Linda Schwab Linda Schwab Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 12, 19 June 1991, Pages 815–816, https://doi.org/10.1093/jnci/83.12.815 Published: 19 June 1991
If Test Is Needed, FDA Will Develop It
Authors: C. vanchieri
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article If Test Is Needed, FDA Will Develop It Get access Cori vanchieri Cori vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 9, 6 May 1992, Page 668, https://doi.org/10.1093/jnci/84.9.668 Published: 06 May 1992
Leukemia Relapse in Donor Cells after Allogeneic Bone-Marrow Transplantation
Authors: Peter E. Newburger, Samuel A. Latt, John M. Pesando, Karen Gustashaw, Margaret Powers, R. S. K. Chaganti, Richard J. O'Reilly
Journal: New England Journal of Medicine (1981)

ABLATIVE chemotherapy with allogeneic bone-marrow transplantation has become an accepted means of therapy for acute leukemia.1 It is the only treatment capable of producing long-term unmaintained remissions in patients with acute lymphoblastic leukemia who have had relapses during the course of conventional chemotherapy, and it has been advocated for acute myeloblastic leukemia in first remission.1 An initially unforeseen and rare form of failure of such therapy has been the relapse of leukemia in donor cells.2 3 4 5 We report here our experience with a patient with acute lymphoblastic leukemia who had a relapse after therapy with high-dose cyclophosphamide, total-body irradiation, and bone-marrow . . .
THU0302 Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced by Intravesical BCG Therapy for Bladder Cancer: A Retrospective Two-Center Study
Authors: Y. Taniguchi, M. Tsuno, T. Karashima, S. Nishiyama, Y. Yoshinaga, K. Ode, K. Ogata, Y. Shimamura, S. Nakayama, T. Shuin, S. Fujimoto, Y. Terada
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Intravesical instillation of BCG is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive arthritis (ReA) and the incidence are known as about 0.5 to 1%. <h3>Objectives</h3> To evaluate clinical characteristics and incidence of Japanese patients with ReA induced by intravesical BCG therapy (iBCG) for bladder cancer. <h3>Methods</h3> The clinical symptoms, laboratory, and imaging findings of Japanese patients who received iBCG (n=405 (134 and 271 in Kochi University Hospital (KUH) and Kurashiki Medical Center (KMC), respectively)) for bladder cancer from March 1997 to October 2012 were retrospectively assessed. Especially, the patients with ReA and conjunctivitis/uveitis were examined. All data are presented as mean ± SD. <h3>Results</h3> Of the patients received iBCG (age 71±10 and 69±11; male/female 95/39 and 215/56 in KUH and KMC, respectively), 40 (30%) and 35 (13%), 41 (31%) and 48 (18%), and 59 (44%) and 73 (27%) in KUH and KMC presented fever, hematuria and painful urination, respectively. ReA was revealed in 3/134 (2.2%) and 3/271 (1.1%), uveitis in 3/134 (2.2%) and 1/271 (0.4%), and conjunctivitis in 12/134 (8.9%) and 14/271 (5.2%) in KUH and KMC, respectively. As the total evaluation, ReA was revealed in 6/405 (1.5%). Moreover, most patients with ReA also had hepatic dysfuntion. All ReA were developed after 3-times of iBCG. Clinical, ultrasound and FDG-PET/CT findings of ReA induced by iBCG showed asymmetric polyarthritis/polyenthesitis pattern in shoulder, sternoclavicular joints, spinous process, sacroiliac joints, ischial tuberosity, hip, knee and ankle. Laboratory examinations showed high CRP (&gt;10mg/dl) and 33% HLA-B27 positivity (in 1 of 3 cases). All ReA patients were improved by treatments with prednisolone and isoniazid. <h3>Conclusions</h3> The incidence of ReA induced by iBCG in Japanese population was 1.5% and it might be almost equal or more than the incidence, 0.5 to 1%, in the Western countries from previous reports. Positive HLA-B27 was revealed in 33% of ReA patients as background in our study, suggesting lower frequency than 51 to 55% in the Western countries. Therefore, besides HLA phenotype, a cross reaction between a mycobacterium epitope and an antigen of joint cartilage might be suggested in the pathogenesis of ReA induced by iBCG in Japan. <h3>Acknowledgements</h3> No funding support <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4230
952 THE IMPACT OF PRIMARY BILIARY CIRRHOSIS (PBC) ON PERCEIVED QUALITY OF LIFE (QoL): THE UK-PBC NATIONAL STUDY
Authors: G. Mells, G. Pells, J. Newton, A. Bathgate, A. Burroughs, M. Heneghan, J. Neuberger, D. Day, S. Ducker, R. Sandford, G. Alexander, D. Jones
Journal: Journal of Hepatology (2013)
P22 The relationship between social deprivation and hospital admissions with acute exacerbation of chronic obstructive pulmonary disease (AECOPD): Abstract P22 Table 1.
Authors: RJ Grecian, SM Grecian, J Wright, H Balata, A Ashish, I Aziz
Journal: Thorax (2013)

<h3>Background </h3> AECOPD is a major source of hospital admissions. Research is underway to reduce such admissions, but the effect of social deprivation on AECOPD hospital admissions and length of stay is unknown. <h3>Aims and Objectives</h3> To analyse the effect of social deprivation on hospital admissions and length of stay in AECOPD. <h3>Methods</h3> Retrospective review of hospitalisation with a primary diagnosis of AECOPD Sep 11–Aug 12 in a UK hospital. Patients were assigned an index of multiple deprivation score based on postcode and subdivided into quintiles. For each quintile, total admissions and median length of stay per admission were calculated and corrected for population size (per 100,000 residents). Fisher’s exact test (two-tailed) was used to compare quintiles. The least deprived quintile represented &lt;5% of the population and was excluded. <h3>Results</h3> There were significantly higher numbers of hospital admissions in patients from more deprived postcodes as compared to affluent areas (p &lt; 0.001). There was no significant difference in median length of stay between quintiles (Table 1). <h3>Conclusions</h3> Patients from socio-economically deprived backgrounds have higher rates of hospital admissions with AECOPD. Deprivation does not influence length of stay; this could be due to a dedicated COPD unit. Increasing healthcare investment in deprived areas should be considered.
ESTUDIO PROSPECTIVO, CONTROLADO Y COMPARATIVO DEL RENDIMIENTO DE LAS NUEVAS AGUJAS PROCORE 19G VS AGUJAS CONVENCIONALES ECHOTIP3 19G, EN EL DIAGNÓSTICO DIFERENCIAL DE LOS TUMORES SUBMUCOSOS
Authors: M Abu-Suboh Abadia, M Masachs Peracaula, M Moris Felgueroso, J Dot Bach, J Armengol Bertroli, A Benages Curell, JC Salord Oses, JR Armengol Miró
Journal: Endoscopy (2012)

Introducción: El rendimiento diagnostico de la citología de las lesiones submucosas es limitado. La precisión diagnóstica de estas lesiones mediante PAAF esta entre 72–80%. Quedando un 25% de las lesiones sin diagnóstico citológico. El objetivo de este estudio es comparar el rendimiento diagnóstico de una aguja de nuevo diseño, que permite la obtención de cilindro histológico (ProCore19G, Cook), con la aguja citológica estándar de 19G (EchoTip 3, Cook). Método: Se realiza un estudio prospectivo controlado y aleatorizado para comparar el rendimiento diagnóstico y la tasa de obtención de cilindro histológico en las lesiones submucosas del tracto gastrointestinal de las agujas de citología 19G (EchoTip 3Cook®) con la nueva aguja 19G (ProCore 19G Cook®). Se incluyeron 20 pacientes consecutivos (edad media 62, hombres 12, mujeres 8), no seleccionados, que eran remitidos para estudio ecoendoscópico de lesiones submucosas. Se utilizó ecoendoscopio radial (UE-160, Olympus) para la caracterización de la lesión y ecoendoscopio lineal (Olympus UCT-140) para la obtención de la muestra. Una vez localizada y caracterizada la lesión, se realiza punción con aguja Pro-Core y EchoTip, según aleatorización. Resultados: Se incluyen 20 pacientes (edad media 62 años, 12 hombres y 8 mujeres).. El tamaño de los tumores submucosos es 25±14mm (media±SD). 5 tumores se localizan en el esófago, 12 en cámara gástrica, 3 en el duodeno. En cada caso se realizó un mínimo de 2 punciones (18 casos 2 punciones, 1 caso 4 punciones, 1 caso 5 punciones). Se obtuvo material para citología en los 20 casos tanto con la aguja pro-core como con la aguja EchoTip (100%), No obstante tan solo se obtuvo diagnóstico citológico en 3 casos con la aguja ProCore (15%), y en 4 casos con la aguja EchoTip. (20%). Se obtuvo cilindro para histología en 19 casos con la aguja Pro-Core (95%) y en 14 casos con la estándar (70%). El diagnóstico histológico se obtuvo en 7 casos con la aguja Pro-Core y en 7 casos con la aguja convencional (35%). Los diagnósticos que se obtuvieron son 6 GIST, 1 leiomioma, 1 tumor neuroendocrino. Conclusión: La nueva aguja Pro-Core, permite obtener cilindro histológico con mayor frecuencia que con la aguja convencional, No obstante en nuestro estudio, y probablemente debido al tamaño de las lesiones, el rendimiento diagnóstico ha sido igual para ambas agujas.
Abstract 3950: Neuropilin-2, a transmembrane glycoprotein receptor, protects prostate cancer cells from stress
Authors: Heyu Zhang, Enfeng Wang, Donald J. Tindall, Kaustubh Datta
Journal: Cancer Research (2010)

Abstract Prostate cancer is the most common cancer and the second leading cause of cancer death in men in the United States. Definitive treatment consists of either radical prostatectomy or radiotherapy followed by androgen deprivation. Although majority of the prostate cancers usually responds to these therapies and can be cured, some of them will eventually relapse. It is believed that the relapsed cancers obtained new ability that facilitates their resistance to these therapeutic stresses. Increased expression of VEGF-C and its receptor Neuropilin-2 (NRP-2) in hormone-refractory and metastatic prostate cancers indicates that the VEGF-C/NRP-2 axis could play an important role in the progression of prostate cancer. Indeed, we observed VEGF-C/Neuropilin-2 axis promotes survival of prostate cancer cells during stress induced by hydrogen peroxide or radiation. Detail signaling events downstream of neuropilin-2 for this stress-resistant function have also been determined. Our findings therefore demonstrated a novel and distinct function of NRP-2 in protecting cancer cells from stress-induced cell death, thereby facilitating cancer recurrence and metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3950.
Improved survival in surgical stage I uterine papillary serous cancer (UPSC) treated with adjuvant platinum-based chemoradiation
Authors: M. G. Kelly, D. O’Malley, P. Hui, J. Dziura, J. McAlpine, M. Azodi, T. J. Rutherford, P. E. Schwartz
Journal: Journal of Clinical Oncology (2005)

5023 Objective: UPSC is an aggressive type of endometrial cancer characterized by a high recurrence rate and a poor prognosis. Prior studies evaluating treatment of UPSC are limited by small numbers of patients and inclusion of unstaged patients. The purpose of this study is to evaluate the efficacy of adjuvant chemoradiation (defined as concomitant vaginal cuff radiation and platinum-based chemotherapy) in a large cohort of stage I UPSC patients. Methods: We identified 182 patients with UPSC who underwent complete surgical staging between 1987–2003. Differences in disease free survival (DFS) and overall survival (OS) were determined by Kaplan-Meier log rank method. Results: 74 of the182 cases were FIGO stage I: 33 stage IA, 29 stage IB and 12 stage IC. Stage IA patients were further divided into 2 groups: patients with no cancer in the hysterectomy specimen (defined as no residual uterine disease, n=12) and patients with residual uterine disease (n=21). Stage IA patients with no residual uterine disease had no recurrences, regardless of adjuvant therapy. Stage IA patients with residual uterine disease treated with chemoradiation had no recurrences (n=7). However, 6 of 14 (43%) stage IA patients with residual uterine disease who did not receive chemoradiation recurred. Stage IA patients with residual uterine disease who were treated with chemoradiation had an improved DFS and OS (p<0.05). 12 patients with stage IB received chemoradiation and none recurred. 10 of 17 (59%) stage IB patients who did not receive chemoradiation recurred. Stage IB patients who were treated with chemoradiation had an improved DFS and OS (p<0.05). 1 of 5 (20%) patients with stage IC who received chemoradiation recurred and 4 of the 7 (57%) stage IC patients who did not receive chemoradiation recurred. Stage IC patients who were treated with chemoradiation had an improved OS (p<0.05). Conclusions: We have identified the largest cohort of surgical stage I UPSC patients in the literature and are the first to show significantly improved survival with chemoradiation. Stage IA patients with no residual uterine disease can be observed. Chemoradiation should be the treatment of choice for all other stage I UPSC patients. No significant financial relationships to disclose.
P17.45 * CARBOPLATIN ALONE AND IN COMBINATION WITH BEVACIZUMAB IN A 5MG/KG EVERY-3-WEEK SCHEDULE, IN PATIENTS WITH RECURRENT GLIOBLASTOMAS: A SINGLE CENTER EXPERIENCE
Authors: G. Kaloshi, B. Cakani, P. Diamandi, G. Brace, A. Rroji, M. Petrela
Journal: Neuro-Oncology (2014)

PURPOSE: Carboplatin (CDDP) and Bevacizumab (BEV) are active in GBM with different profiles of toxicity. In a previous report, we have demonstrated the efficacy of Bevacizumab in a 5mg/kg every 3 week schedule We investigated the efficacy of BEV in combination with CDDP vs CDDP alone in patients with recurrent glioblastomas (GBMs) in a phase II, single-center, non-comparative study. MATERIAL AND METHODS: patients with progression disease (PD) following surgery, RT and TMZ, received CDDP at AUC 5 alone or in combination with BEV 5mg/kg and every 3 weeks for recurrent GBMs between June 2010 and December 2013. Baseline characteristics and outcomes after treatment were recorded. Primary end points were progression-free survival and objective response rate. Secondary end points included safety and overall survival. RESULTS: 48 patients (median age 43 (range 22.4-74.8); M/F 28/20) were enrolled into the study. The median number of cycles in each group was 5 CCDP cycles and 6 CDDP+ BEV (range 2 - 8). No toxicities or intracerebral bleeding were observed. In the BEV + CDDP group 8 patients (35%) had partial response, 9 of them (39%) had minor response, 2 had stable disease and 4 patients (17%) had progressive disease, whereas in the other group 2 patients had partial response, 4 minor responses, 10 had stable disease and 9 experienced PD. Thus, the objective response rate was 64% vs 24%, respectively (p = 0.003). In BEV + CDDP and CDDP alone groups, estimated median PFS was 6.7 vs 5.1 respectively (p = 0.09); and median OS were 7.6 vs 8.3 months (p = 0.66) respectively. CONCLUSIONS: Association of BV to CDDP seemed to improve response rate in recurrent GBMs. However, the clinical benefit of this interesting approach needs a validation in a larger patient cohort.
Prenatal Diagnosis of Sickle-Cell Anemia in the First Trimester of Pregnancy
Authors: Michel Goossens, Yves Dumez, Liliana Kaplan, Mieke Lupker, Claude Chabret, Roger Henrion, Jean Rosa
Journal: New England Journal of Medicine (1983)

To investigate the usefulness of chorionic biopsy for prenatal diagnosis of sickle-cell anemia by restriction-endonuclease analysis of fetal DNA, we studied 30 pregnancies before elective abortion. When the reproducibility of the technique for obtaining adequate DNA samples was established, we successfully applied the test to five pregnancies at risk for sickle-cell anemia. In two cases, sickle-cell disease of the fetus led to a decision to terminate the pregnancy. In three other cases, a normal or AS genotype was demonstrated. One normal infant has been born, and one other pregnancy is continuing normally. In one case in which fetal death was observed three weeks after sampling, placental abnormalities found on histologic examination were compatible with a chromosomal aberration. Our study shows that chorionic biopsy is feasible for the prenatal diagnosis of sickle-cell disease before the 10th gestational week. If subsequent experience demonstrates this technique to be safe enough for mother and fetus, the ability to test in early pregnancy may make prenatal diagnosis acceptable to more couples at risk for serious genetic disorders.
Patient Organizations and Research on Rare Diseases
Authors: Julie R. Ingelfinger, Jeffrey M. Drazen
Journal: New England Journal of Medicine (2011)

There are an estimated five women per million in the United States who suffer from lymphangioleiomyomatosis (LAM), a rare and devastating disease that almost exclusively strikes young women.13 These patients have progressive loss of lung function, and many die from respiratory failure. Until recently, a diagnosis of LAM was a medical anomaly, and a woman who received this diagnosis had little cause for hope. The disease was likely to be managed symptomatically by physicians unfamiliar with the disease.That all changed about 15 years ago, when LAM was diagnosed in a 22-year-old woman who had a bleak picture painted . . .